Objectives: To determine effects of quetiapine on polysomnographicrecorded sleep architecture and parameters.
Introduction and Hypothesis: Quetiapine receptor profile suggests that sleep-inducing and sleep-modifying properties may be causing changes in sleep architecture and parameter, which may have therapeutic value.
Methods: A cross-sectional retrospective study conducted at the sleep center. Polysomnographic sleep records were selected and reviewed from among patients who presented over 24-months for evaluation. Twenty-one patients were selected and matched based on age, sex, body-mass index (BMI), and the presence/absence of obstructive sleep apnea (OSA) to control subjects without quetiapine. Correlation analysis was performed to assess the association of quetiapine with sleep architecture and parameters.
Results: Quetiapine was not significantly associated with altered sleep efficiency, sleep latency, wake time after sleep onset, or the relative percentage of sleep stages. A notablebut not significant (p = 0.08), increase in the rapid eye movement latency was observed.
Conclusions: Among the study population quetiapine was not found associated with changes in sleep architecture and parameters.
Hypothesis: Use of quetiapine will be associated with shortened sleep latency (SL), increased total sleep time (TST), and increased non-rapid eye movement (NREM) stage III (most restorative sleep).
DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet. 2001;40:509-22.
Cohrs S, Rodenbeck A, Guan Z, et al. Sleep-promoting properties of quetiapine in healthy subjects. Psychopharmacology (Berl). 2004;174:421-429.
Wiegand MH, Landry F, Bruckner T, et al. Quetiapine in primary insomnia: a pilot study. Psychopharmacology (Berl). 2008;196:337-338.
Gedge L, Lazowski L, Murray D, et al. Effects of quetiapine on sleep architecture in patients with unipolar or bipolar depression. Neuropsychiatric Disease and Treatment. 2010;6:501-508.
Endicott J, Paulsson B, Gustafsson U, et al. Quetiapine monotherapy in the treatment of depressive episodes of bipolar I and II disorder: improvements in quality of life and quality of sleep. Journal of Affective Disorders. 2008;111:306-319.
Tassniyom K, Paholpak S, Tassniyom S, et al. Quetiapine for primary insomnia: a double blind, randomized controlled trial. J Med Association Thai. 2010;93(6):729-734.
Linden M, Thiels C. Epidemiology of prescriptions for neuroleptic drugs: tranquilizers rather than antipsychotics. Pharmacopsychiatry. 2001;34:150-154.
Baune BT, Caliskan S, Todder D. Effects of adjunctive antidepressant therapy with quetiapine on clinical outcome, quality of sleep and daytime motor activity in patients with treatment-resistant depression. Hum Psychopharmacology. 2007;22:1-9.
Calabrese JR, Keck PE, MacFadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in treatment of bipolar I and II depression, Am J Psychiatry. 2005;162:1351-1360.
Endicott J, Rajagopalan K, Minkwitz M, et al. BOLDER Study Group. A randomized, double-blind, placebo-controlled study of quetiapine in the treatment of bipolar I and II depression: improvements in quality of life. IntClin Psychopharmacology. 2007;22:29-37.
Sokolski KN, Brown BJ. Quetiapine for insomnia associated with refractory depression exacerbated by phenelzine. Ann Pharmacotherapy. 2006;40:567-570.
Todder D, Caliskan S, Baune BT. Night locomotor activity and quality of sleep in quetiapine-treated patients with depression. J Clin Pharmacology. 2006;26:638-642.
Wetter TC, Brunner J, Bronisch T. Restless legs syndrome probably induced by risperidone treatment. Pharmacopsychiatry. 2002;35:109-111.
Hinze Selch D, Mullington J, Orth A, et al. Effects of clozapine on sleep: a longitudinal study. Biol Psychiatry. 1997;42:260- 266.
Salin Pascual RJ, Herrera Estrella M, Galicia Polo L, et al. Olanzapine acute administration in schizophrenic patient's increases delta sleep and sleep efficiency. Biol Psychiatry. 1999;46:141-143.
Sharpley AL, Vassallo CM, Cowen PJ. Olanzapine increases slow-wave sleep: evidence for blockade of central 5-HT (2C) receptors in vivo. Biol Psychiatry. 2000;47:486- 470.
Hamner MB, Deitsch SE, Brodrick PS, et al. Quetiapine treatment in patients with post-traumatic stress disorder: an open trial of adjunctive therapy. J Clin Psychopharmacology. 2003;23:15-20.